Limits...
c-erbB-2 protein expression in astrocytic tumors of the brain.

Reszeć J, Bernaczyk PS, Milewski R, Chyczewski L, Mariak Z - Med. Sci. Monit. (2011)

Bottom Line: There were no statistically significant differences between the examined groups.The strongest c-erbB-2 immunoexpression was observed in low grade astrocytomas (diffuse astrocytomas G2); in the glioblastoma group the c-erbB-2 protein expression was weak and 17.4% of cases were negative.C-erbB-2 protooncogene alteration is an early phenomenon in glial tumor development and progression.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland. joannareszec@gmail.com

ABSTRACT

Background: Astrocytic tumors are the primary brain tumors, which often progress to glioblastoma, a highly malignant neoplasm of the central nervous system. There is much new data regarding to the formation and progression of these tumors; however, glioblastoma remains one of the most fatal neoplasms in humans. The aim of the study was to evaluate the role of c-erbB-2 protein expression in various groups of astrocytic tumors.

Material/methods: 65 cases of astrocytic tumors were divided into 3 groups: diffuse astrocytoma (group I; n=17 cases), anaplastic astrocytoma (group II; n=23 cases) and glioblastoma (group III; n=25 cases). C-erbB-2 protein expression was estimated semiquantitatively on immunohistochemically stained tissue sections using antibodies against c-erbB-2 protein. Statistical analysis was performed in all examined groups.

Results: The c-erbB-2 protein expression was observed in 15 out of 17 cases (88.3%) in group I, 22 out of 25 cases (88%) cases in group II, and in 19 out of 23 cases (82.6%) in group III. There were no statistically significant differences between the examined groups. The strongest c-erbB-2 immunoexpression was observed in low grade astrocytomas (diffuse astrocytomas G2); in the glioblastoma group the c-erbB-2 protein expression was weak and 17.4% of cases were negative.

Conclusions: C-erbB-2 protooncogene alteration is an early phenomenon in glial tumor development and progression.

Show MeSH

Related in: MedlinePlus

Nonneoplastic cerebral tissue with negative c-erbB-2 immunoexpression. Magn 200×.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3539622&req=5

f1-medscimonit-17-8-br216: Nonneoplastic cerebral tissue with negative c-erbB-2 immunoexpression. Magn 200×.

Mentions: Appropriate positive and negative controls were performed. Negative controls were performed using a nonimmunized IgG replacing the primary antibody. Known c-erbB-2 protein expressing breast cancer and lymph node with metastatic disease were used as positive controls. The c-erbB-2 protein expression was evaluated and compared in all of the groups and the intensity of the staining was related to the nonneoplastic cerebral tissue containing neocortex and adjacent white matter (Figure 1).


c-erbB-2 protein expression in astrocytic tumors of the brain.

Reszeć J, Bernaczyk PS, Milewski R, Chyczewski L, Mariak Z - Med. Sci. Monit. (2011)

Nonneoplastic cerebral tissue with negative c-erbB-2 immunoexpression. Magn 200×.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3539622&req=5

f1-medscimonit-17-8-br216: Nonneoplastic cerebral tissue with negative c-erbB-2 immunoexpression. Magn 200×.
Mentions: Appropriate positive and negative controls were performed. Negative controls were performed using a nonimmunized IgG replacing the primary antibody. Known c-erbB-2 protein expressing breast cancer and lymph node with metastatic disease were used as positive controls. The c-erbB-2 protein expression was evaluated and compared in all of the groups and the intensity of the staining was related to the nonneoplastic cerebral tissue containing neocortex and adjacent white matter (Figure 1).

Bottom Line: There were no statistically significant differences between the examined groups.The strongest c-erbB-2 immunoexpression was observed in low grade astrocytomas (diffuse astrocytomas G2); in the glioblastoma group the c-erbB-2 protein expression was weak and 17.4% of cases were negative.C-erbB-2 protooncogene alteration is an early phenomenon in glial tumor development and progression.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland. joannareszec@gmail.com

ABSTRACT

Background: Astrocytic tumors are the primary brain tumors, which often progress to glioblastoma, a highly malignant neoplasm of the central nervous system. There is much new data regarding to the formation and progression of these tumors; however, glioblastoma remains one of the most fatal neoplasms in humans. The aim of the study was to evaluate the role of c-erbB-2 protein expression in various groups of astrocytic tumors.

Material/methods: 65 cases of astrocytic tumors were divided into 3 groups: diffuse astrocytoma (group I; n=17 cases), anaplastic astrocytoma (group II; n=23 cases) and glioblastoma (group III; n=25 cases). C-erbB-2 protein expression was estimated semiquantitatively on immunohistochemically stained tissue sections using antibodies against c-erbB-2 protein. Statistical analysis was performed in all examined groups.

Results: The c-erbB-2 protein expression was observed in 15 out of 17 cases (88.3%) in group I, 22 out of 25 cases (88%) cases in group II, and in 19 out of 23 cases (82.6%) in group III. There were no statistically significant differences between the examined groups. The strongest c-erbB-2 immunoexpression was observed in low grade astrocytomas (diffuse astrocytomas G2); in the glioblastoma group the c-erbB-2 protein expression was weak and 17.4% of cases were negative.

Conclusions: C-erbB-2 protooncogene alteration is an early phenomenon in glial tumor development and progression.

Show MeSH
Related in: MedlinePlus